Elevance Health (ELV) Raises Full-Year Guidance After Q1 2026 Beat

NYSE: ELV · April 22, 2026 · 3 min read

Elevance Health (NYSE: ELV) climbed $8.75, or 2.74%, to $328.11 on Wednesday after the company reported first-quarter 2026 results that prompted management to raise its full-year adjusted earnings guidance. The insurer now targets annual adjusted profit of at least $26.75 per share, citing confidence in its ability to contain medical costs across its membership base.

Q1 2026 At a Glance

• Operating revenue: $49.5 billion, up 1.5% from Q1 2025
• Diluted EPS (GAAP): $8.00
• Adjusted diluted EPS: $12.58, which included approximately $1 per share of non-recurring items
• Full-year adjusted EPS guidance: raised to at least $26.75
• Trailing P/E: 13.0x | Forward P/E: 11.3x
• Net margin: 2.8% | Gross margin: 25.6% | Operating margin: 1.5%
• Revenue growth (YoY): 9.5% | Earnings growth (YoY): 36.3%
• Market cap: $72.4 billion
• 52-week range: $273.71 – $432.93

What Drove the Results

The guidance raise reflects Elevance's emphasis on keeping medical cost trends in check — a priority that has become central to the managed-care sector's narrative in 2026. The $12.58 adjusted EPS figure benefited from strong underlying operating performance alongside roughly $1 per share in non-recurring items, per the company's earnings release confirmed by its April 22 SEC 8-K filing under Item 9.01.

The 36.3% year-over-year earnings growth stands out given that revenue expanded a comparatively modest 9.5%, suggesting meaningful progress on the expense side rather than top-line acceleration alone. With a forward P/E of 11.3x against that earnings trajectory, the valuation case appears tied closely to whether cost discipline can be sustained through the remainder of the year.

Wall Street View

Analyst sentiment on Elevance Health has held steady heading into this report. As of April 1, 2026, the consensus stood at 5 Strong Buy, 10 Buy, and 13 Hold ratings, with zero Sell or Strong Sell calls — an identical distribution to the prior month's read. The absence of any downward shift in recommendations, even as the stock has traded 19.8% below its level a year ago, suggests the Street views the recent weakness as a valuation opportunity rather than a fundamental deterioration.

Investor Takeaway

Elevance Health's decision to raise full-year guidance following a quarter in which adjusted EPS reached $12.58 offers a constructive signal for investors who have watched the stock pull back from its 52-week high of $432.93. The unchanged analyst consensus — uniformly positive, with no Sell ratings — reinforces that institutional opinion has not soured despite a difficult twelve months for the shares. At a forward P/E of 11.3x and with management citing cost control as a key lever, the fundamental story rests on execution in the quarters ahead.